Centessa Pharmaceuticals plc
CNTA
$16.51
-$0.495-2.91%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -3.42% | -10.01% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 19.39% | -38.62% | |||
| Operating Income | -77.58% | 58.73% | |||
| Income Before Tax | -100.36% | 77.57% | |||
| Income Tax Expenses | -44.31% | 33.05% | |||
| Earnings from Continuing Operations | -92.63% | 76.52% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -92.63% | 76.52% | |||
| EBIT | -77.58% | 58.73% | |||
| EBITDA | -78.10% | 58.97% | |||
| EPS Basic | -91.65% | 76.69% | |||
| Normalized Basic EPS | -99.40% | 67.78% | |||
| EPS Diluted | -91.65% | 76.69% | |||
| Normalized Diluted EPS | -99.40% | 67.78% | |||
| Average Basic Shares Outstanding | 0.48% | 0.74% | |||
| Average Diluted Shares Outstanding | 0.48% | 0.74% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||